Medically reviewed by the Celva medical team · June 2026
Could this reach
your case?
This is an evaluation-first program for neurologic, cardiovascular, and autoimmune disease. The honest read happens before you fly, before you pay, and before hope gets ahead of evidence. If there's a real biologic case to make for your situation, we'll find it. If there isn't, we'll tell you straight.
We only move forward when a case appears clinically appropriate and expectations are realistic. Declines come with reasons and, where appropriate, a referral.
Indication with biologic plausibility, imaging that matches, and realistic expectations.
We do not enroll families in expensive therapy when the biologic case isn't there.
The honest
position.
Complex disease varies enormously in mechanism, time course, and how reachable it is with cell signaling. MSC therapy has stronger rationale in some indications than others. The whole point of the evaluation is to tell those apart, for your case specifically.
The families most likely to reach us have already heard every version of hope and every version of no. Our job isn't to add another "maybe." It's to read the case honestly and say yes, no, or not yet, with reasons.
If your case has a plausible indication and reasonable imaging, we'll evaluate carefully. If it doesn't, we'll tell you why not, and where to look next.
The cell type is matched to the target, not used off the shelf. Across these conditions we build on allogeneic umbilical-cord (Wharton's jelly) MSCs, which secrete higher levels of neurotrophic, immune-modulating, and pro-repair signaling factors than marrow-derived cells, often blended with bone-marrow MSCs depending on the target. That signaling environment, supporting your body's own repair rather than replacing tissue, is the mechanism we rely on, which is also why it has limits.
We don't run blanket "stem cells for Alzheimer's" or "stem cells for autism" marketing, and we never promise a result. We look at each case on its own: where there is a documented rationale and a realistic goal, the medical team may take it on; where there isn't, we say so plainly.
Where the biology
can reach.
Parkinson's, post-stroke, neuropathy
Early-to-mid Parkinson's as an adjunct, chronic post-stroke deficit, and peripheral neuropathy where there is still nerve structure to support and inflammation to influence.
- Imaging that matches
- Optimized on current care
- Realistic goals
Ischemic cardiomyopathy
Reduced ejection fraction, stable on guideline-directed therapy, still followed by your cardiologist. The evidence is early; we treat it as an adjunct, never a replacement for your cardiac care.
- Stable on therapy
- Cardiologist involved
- Adjunct intent
Inflammatory-driven cases
Select MS, dysautonomia, and post-viral conditions with a demonstrated inflammatory component, where systemic immune modulation has a rationale.
- Documented inflammatory markers
- Prior therapy trials documented
- Realistic goals
Early-to-mid ALS
Accepted for quality-of-life support only. We are explicit up front: this is palliative, not disease-modifying. Cell therapy does not cure ALS.
- Early-to-mid stage only
- Quality-of-life goals
- Specialist kept informed
How a case
is evaluated.
Written submission
Diagnosis, imaging, medication history, prior therapy trials, goals. Submitted in writing before any call.
Physician team review
Celva's medical team reviews the written submission and imaging against the evidence for your condition. Decision may land here.
Conversation
If the profile merits further evaluation, an extended call follows, and the physician team joins. Questions both ways.
Accept, decline, or defer
Accept with a written plan. Decline with reasons and referrals where appropriate. Defer pending additional imaging or trials.
Candidacy
questions.
Q.01My specialist said stem cells won't help. Why submit anyway?
Q.02Why decline cases other clinics accept?
Q.03Is there any version of stem cell therapy that helps my condition?
Keep
reading.
Submit for
honest evaluation.
The written intake is the first read. The purpose is to decide well, not to fill a schedule.